Pfizer and Astellas have unveiled results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use.
The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).
The Peter Sowerby Foundation has issued an open call to source a suitable project for up to £2 million of funding as part of the Foundation’s Health Breakthrough funding strand.
The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have published draft guidance on antimicrobial prescribing for hospital-acquired and community-acquired pneumonia, setting out a strategy designed to optimise antibiotic use and reduce antibiotic resistance.
AbbVie has signed a deal with Teneobio to develop a B-cell maturation antigen (BCMA)-targeting bispecific antibody for multiple myeloma.
A new study has found that 10% of adults aged over 75 have major depressive disorder, and over one third sub-threshold depressive symptoms.
SAW Diagnostics has announced that Innovate UK has awarded the company a £1.5 million grant in support of its low-cost sample preparation system, for use in infectious disease detection and other applications.
Gilead’s selonsertib has failed to hit a key target in a late-stage study involving patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Takeda has announced that the European Commission has extended the current marketing authorisation of Adcetris to include treatment of adults with previously untreated CD30+ Stage IV Hodgkin lymphoma.
A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
Professor Dame Sally Davies will leave her post as chief medical officer for England and chief medical officer advisor to the UK government later this year to take up a new role.
The Association of the British Pharmaceutical Industry (ABPI) has expressed fears that the UK will drop out of the “safest medicines system in the world” in the event of no-deal Brexit.
UniQure’s experimental gene therapy has shown sustained Factor IX activity in a Phase II study assessing its potential to treat haemophilia B.
Grey Wolf Therapeutics has completed a £10 million series A financing to fund development of immuno-oncology therapies to increase tumour visibility.
